283 related articles for article (PubMed ID: 30585088)
41. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in computer-aided drug design as applied to anti-influenza drug discovery.
Mallipeddi PL; Kumar G; White SW; Webb TR
Curr Top Med Chem; 2014; 14(16):1875-89. PubMed ID: 25262796
[TBL] [Abstract][Full Text] [Related]
43. The pharmacological management of severe influenza infection - 'existing and emerging therapies'.
Mc Mahon A; Martin-Loeches I
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):81-95. PubMed ID: 27797595
[TBL] [Abstract][Full Text] [Related]
44. The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.
Stevaert A; Naesens L
Med Res Rev; 2016 Nov; 36(6):1127-1173. PubMed ID: 27569399
[TBL] [Abstract][Full Text] [Related]
45. Influenza virus resistance to antiviral therapy.
van der Vries E; Schutten M; Fraaij P; Boucher C; Osterhaus A
Adv Pharmacol; 2013; 67():217-46. PubMed ID: 23886002
[TBL] [Abstract][Full Text] [Related]
46. Discovery of Potent Antivirals against Amantadine-Resistant Influenza A Viruses by Targeting the M2-S31N Proton Channel.
Li F; Ma C; Hu Y; Wang Y; Wang J
ACS Infect Dis; 2016 Oct; 2(10):726-733. PubMed ID: 27657178
[TBL] [Abstract][Full Text] [Related]
47. Progress of small molecular inhibitors in the development of anti-influenza virus agents.
Wu X; Wu X; Sun Q; Zhang C; Yang S; Li L; Jia Z
Theranostics; 2017; 7(4):826-845. PubMed ID: 28382157
[TBL] [Abstract][Full Text] [Related]
48. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
Takashita E; Ejima M; Ogawa R; Fujisaki S; Neumann G; Furuta Y; Kawaoka Y; Tashiro M; Odagiri T
Antiviral Res; 2016 Aug; 132():170-7. PubMed ID: 27321665
[TBL] [Abstract][Full Text] [Related]
49. Genetic screens for the control of influenza virus replication: from meta-analysis to drug discovery.
de Chassey B; Meyniel-Schicklin L; Aublin-Gex A; André P; Lotteau V
Mol Biosyst; 2012 Apr; 8(4):1297-303. PubMed ID: 22307679
[TBL] [Abstract][Full Text] [Related]
50. Intrahost dynamics of antiviral resistance in influenza A virus reflect complex patterns of segment linkage, reassortment, and natural selection.
Rogers MB; Song T; Sebra R; Greenbaum BD; Hamelin ME; Fitch A; Twaddle A; Cui L; Holmes EC; Boivin G; Ghedin E
mBio; 2015 Apr; 6(2):. PubMed ID: 25852163
[TBL] [Abstract][Full Text] [Related]
51. John F. Enders lecture 2006: antivirals for influenza.
Ong AK; Hayden FG
J Infect Dis; 2007 Jul; 196(2):181-90. PubMed ID: 17570104
[TBL] [Abstract][Full Text] [Related]
52. Viral M2 ion channel protein: a promising target for anti-influenza drug discovery.
Moorthy NS; Poongavanam V; Pratheepa V
Mini Rev Med Chem; 2014; 14(10):819-30. PubMed ID: 25342196
[TBL] [Abstract][Full Text] [Related]
53. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus.
Rungrotmongkol T; Intharathep P; Malaisree M; Nunthaboot N; Kaiyawet N; Sompornpisut P; Payungporn S; Poovorawan Y; Hannongbua S
Biochem Biophys Res Commun; 2009 Jul; 385(3):390-4. PubMed ID: 19463784
[TBL] [Abstract][Full Text] [Related]
54. Surveillance for antiviral resistance among influenza viruses circulating in Algeria during five consecutive influenza seasons (2009-2014).
Ait-Aissa A; Derrar F; Hannoun D; Gradi EA; Scaravelli D; Bouslama Z
J Med Virol; 2018 May; 90(5):844-853. PubMed ID: 29315673
[TBL] [Abstract][Full Text] [Related]
55. Modeling the effects of drug resistant influenza virus in a pandemic.
Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
[TBL] [Abstract][Full Text] [Related]
56. Advances in the structure-based design of the influenza A neuraminidase inhibitors.
Mitrasinovic PM
Curr Drug Targets; 2010 Mar; 11(3):315-26. PubMed ID: 20210756
[TBL] [Abstract][Full Text] [Related]
57. [Sensitivity of the epidemic and pandemic influenza virus strains to zanamivir (Relenze) in in vitro experiments].
L'vov DK; Burtseva EI; Galegov GA; Beliakova NV; Shevchenko ES; Kolobukhina LV; Merkulova LN; Prilipov AG; Leneva IA; Baranov NI; Gorelikov VN; Abramov DD
Vopr Virusol; 2010; 55(6):10-4. PubMed ID: 21381333
[TBL] [Abstract][Full Text] [Related]
58. [Clinical characteristics and molecular epidemiology of the novel influenza A (H1N1) infection in children in Shanghai].
Wang XS; Cai JH; Yao WL; Ge YL; Zhu QR; Zeng M
Zhonghua Er Ke Za Zhi; 2013 May; 51(5):356-61. PubMed ID: 23941842
[TBL] [Abstract][Full Text] [Related]
59. Antivirals for influenza: historical perspectives and lessons learned.
Hayden FG
Antiviral Res; 2006 Sep; 71(2-3):372-8. PubMed ID: 16815563
[TBL] [Abstract][Full Text] [Related]
60. China makes an impressive breakthrough in avian influenza virus research - Discovering the "heart" of avian infl uenza virus.
Li YG; Wu JF; Li X
Drug Discov Ther; 2009 Feb; 3(1):1. PubMed ID: 22495459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
